Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

Abstract Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal or vulvar SCC who were treated with single-agent pembrolizumab as part of a phase II basket clinical tr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jeffrey A. How, Amir A. Jazaeri, Pamela T. Soliman, Nicole D. Fleming, Jing Gong, Sarina A. Piha-Paul, Filip Janku, Bettzy Stephen, Aung Naing
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/aeeef12d0e0e4b5d9337328c2487a6ed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aeeef12d0e0e4b5d9337328c2487a6ed
record_format	dspace
spelling	oai:doaj.org-article:aeeef12d0e0e4b5d9337328c2487a6ed2021-12-02T13:30:10ZPembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial10.1038/s41598-021-83317-72045-2322https://doaj.org/article/aeeef12d0e0e4b5d9337328c2487a6ed2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83317-7https://doaj.org/toc/2045-2322Abstract Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal or vulvar SCC who were treated with single-agent pembrolizumab as part of a phase II basket clinical trial to evaluate efficacy and safety. Two cases of recurrent and metastatic vaginal SCC, with multiple prior lines of systemic chemotherapy and radiation, received pembrolizumab. One patient had significant reduction (81%) in target tumor lesions prior to treatment discontinuation at cycle 10 following confirmed progression of disease with new metastatic lesions (stable disease by irRECIST criteria). In contrast, the other patient with vaginal SCC discontinued treatment after cycle 3 due to disease progression. Both patients had PD-L1 positive vaginal tumors and tolerated treatment well. One case of recurrent vulvar SCC with multiple surgical resections and prior progression on systemic carboplatin had a 30% reduction in her target tumor lesions following pembrolizumab treatment with a PD-L1 positive tumor. Treatment was discontinued for grade 3 mucositis after cycle 5. Pembrolizumab may provide some clinical benefit to some patients with vaginal or vulvar SCC and is overall safe to utilize in this population. Future studies are needed to evaluate the efficacy of pembrolizumab in these rare tumor types and to identify predictive biomarkers of response.Jeffrey A. HowAmir A. JazaeriPamela T. SolimanNicole D. FlemingJing GongSarina A. Piha-PaulFilip JankuBettzy StephenAung NaingNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jeffrey A. How Amir A. Jazaeri Pamela T. Soliman Nicole D. Fleming Jing Gong Sarina A. Piha-Paul Filip Janku Bettzy Stephen Aung Naing Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
description	Abstract Vaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal or vulvar SCC who were treated with single-agent pembrolizumab as part of a phase II basket clinical trial to evaluate efficacy and safety. Two cases of recurrent and metastatic vaginal SCC, with multiple prior lines of systemic chemotherapy and radiation, received pembrolizumab. One patient had significant reduction (81%) in target tumor lesions prior to treatment discontinuation at cycle 10 following confirmed progression of disease with new metastatic lesions (stable disease by irRECIST criteria). In contrast, the other patient with vaginal SCC discontinued treatment after cycle 3 due to disease progression. Both patients had PD-L1 positive vaginal tumors and tolerated treatment well. One case of recurrent vulvar SCC with multiple surgical resections and prior progression on systemic carboplatin had a 30% reduction in her target tumor lesions following pembrolizumab treatment with a PD-L1 positive tumor. Treatment was discontinued for grade 3 mucositis after cycle 5. Pembrolizumab may provide some clinical benefit to some patients with vaginal or vulvar SCC and is overall safe to utilize in this population. Future studies are needed to evaluate the efficacy of pembrolizumab in these rare tumor types and to identify predictive biomarkers of response.
format	article
author	Jeffrey A. How Amir A. Jazaeri Pamela T. Soliman Nicole D. Fleming Jing Gong Sarina A. Piha-Paul Filip Janku Bettzy Stephen Aung Naing
author_facet	Jeffrey A. How Amir A. Jazaeri Pamela T. Soliman Nicole D. Fleming Jing Gong Sarina A. Piha-Paul Filip Janku Bettzy Stephen Aung Naing
author_sort	Jeffrey A. How
title	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
title_short	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
title_full	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
title_fullStr	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
title_full_unstemmed	Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
title_sort	pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase ii basket trial
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/aeeef12d0e0e4b5d9337328c2487a6ed
work_keys_str_mv	AT jeffreyahow pembrolizumabinvaginalandvulvarsquamouscellcarcinomaacaseseriesfromaphaseiibaskettrial AT amirajazaeri pembrolizumabinvaginalandvulvarsquamouscellcarcinomaacaseseriesfromaphaseiibaskettrial AT pamelatsoliman pembrolizumabinvaginalandvulvarsquamouscellcarcinomaacaseseriesfromaphaseiibaskettrial AT nicoledfleming pembrolizumabinvaginalandvulvarsquamouscellcarcinomaacaseseriesfromaphaseiibaskettrial AT jinggong pembrolizumabinvaginalandvulvarsquamouscellcarcinomaacaseseriesfromaphaseiibaskettrial AT sarinaapihapaul pembrolizumabinvaginalandvulvarsquamouscellcarcinomaacaseseriesfromaphaseiibaskettrial AT filipjanku pembrolizumabinvaginalandvulvarsquamouscellcarcinomaacaseseriesfromaphaseiibaskettrial AT bettzystephen pembrolizumabinvaginalandvulvarsquamouscellcarcinomaacaseseriesfromaphaseiibaskettrial AT aungnaing pembrolizumabinvaginalandvulvarsquamouscellcarcinomaacaseseriesfromaphaseiibaskettrial
_version_	1718392995448881152

Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

Ejemplares similares